Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanadaBis CapitalTSXV:CANB Receivables Turnover is 2.51 as of Oct. 2025. The stock has 6 warning signs investors should review. Among 950 Drug Manufacturers companies, CanadaBis Capital ranks better than 82.32% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CanadaBis Capital's Revenue for the
three
months ended in Oct. 2025 was C$3.26 Mil. CanadaBis Capital's average Accounts Receivable for the
three
months ended in Oct. 2025 was C$1.30 Mil.
Hence, CanadaBis Capital's Receivables Turnover for the
three
months ended in Oct. 2025 was 2.51.
CanadaBis Capital (TSXV:CANB) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
CanadaBis Capital Receivables Turnover Related Terms
CanadaBis Capital Receivables Turnover Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:CANB vs NPHC, BSPK, CPMD: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanadaBis Capital (TSXV:CANB) has a Receivables Turnover of 2.51 as of Oct. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CanadaBis Capital and its competitors. According to the industry distribution chart, CanadaBis Capital ranks #168 out of 950 companies in the Drug Manufacturers industry, placing it in the top 17.7%.
Is CanadaBis Capital's Receivables Turnover too high?
CanadaBis Capital's current Receivables Turnover is 2.51. The Drug Manufacturers industry median Receivables Turnover is 5.07. CanadaBis Capital's value of 2.51 is 50.5% below this industry median. Based on the distribution chart, CanadaBis Capital ranks #168 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CanadaBis Capital's Receivables Turnover compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #168 out of 950 companies for Receivables Turnover. This places CanadaBis Capital in the top 18% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. CanadaBis Capital's value of 2.51 is 50.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanadaBis Capital's current Receivables Turnover of 2.51 is 50.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CanadaBis Capital and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current Receivables Turnover is 2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current Receivables Turnover of 2.51. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current Receivables Turnover is 2.51 and 50.5% below the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current Receivables Turnover is 2.51 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 
